In this open-label study, the disposition of fleroxacin in liver disease in 12 healthy male volunteers, 6 male cirrhotics without ascites (group A), and 6 male cirrhotics with ascites (group B) was evaluated. Fleroxacin (400 mg) was administered orally and intravenously to each subject in a random crossover fashion. Fleroxacin was completely absorbed and achieved similar peak concentrations in plasma in all three study groups (P > 0.05).
Fleroxacin [6,8- difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-quinoline-3-carboxylic acid; AM-833; Ro 23-6240] is a new fluoroquinolone derivative. It possesses a broad antibacterial spectrum and potent activity in vitro against gram-positive and gram-negative bacteria (MIC for 90% of isolates, <0.05 to 2 mg/liter), including Pseudomonas aeruginosa, methicillin-resistant staphylococci (MIC for 90% of isolates, .0.5 to 4.0 mg/liter), and ,B-lactamase-producing bacteria resistant to broad-spectrum cephalosporins (16) . The overall activity of fleroxacin is roughly comparable to those of norfloxacin, enoxacin, lomefloxacin, ofloxacin, and pefloxacin (1, 3, 5) .
Fleroxacin is rapidly and completely absorbed from the gastrointestinal tract (19, 20) . After one single oral dose of 400 mg, fleroxacin reaches peak concentrations in plasma (Cm.j) of 4.2 to 6.1 mg/liter within 1 to 2 h (25, 29) .
Fleroxacin is well distributed into interstitial fluid and various tissues (20, 21, 26, 30) . Fleroxacin is primarily renally eliminated, with 50 to 60% of the drug being excreted unchanged. It has an extended half-life (t1/2) (10.8 h; range, 7 to 14 h), which allows for once-a-day dosing (7, 15, 25) . The protein binding of fleroxacin in human serum is low (23 to 32%) (12, 14, 15, 25) and is comparable to those of other fluoroquinolones.
Fleroxacin is metabolized in humans by the liver to a small extent via oxidation, demethylation, and glucuronidation (11, 22, 28) . The active N-demethyl fleroxacin and the inactive fleroxacin N-oxide were identified as the major metabolites in plasma and urine. Only 4 to 6% of the fleroxacin dose has been found to be excreted as the N-demethyl and N-oxide metabolites (22) .
Because metabolism by the liver appears to represent only a minor pathway for fleroxacin elimination, the use of this drug seems justified in patients afflicted by liver impairment. However, at this point it is unknown whether the hepatic * Corresponding author. elimination of fleroxacin is modified in the setting of liver disease. Such a modification could potentially cause the accumulation of the parent drug, an active metabolite, or both. Hence, the focus of this study was to determine any alterations in the disposition of fleroxacin in patients with liver cirrhosis of increasing severity, as characterized by the absence or presence of ascites. run, a number of quality control samples (spiked plasma or urine samples) covering the complete range of quantification were analyzed to ensure precision and reproducibility. The bias for unchanged fleroxacin ranged from -3.6 to +6.9% for the plasma samples and from -4.3 to +2.2% for the urine samples. The bias was defined as [(found concentrationspiked concentration)/spiked concentration] x 100. The inter-and intraday coefficients of variation for fleroxacin and metabolites over the concentration range studied were less than 6% (27) .
MATERIALS AND METHODS

Study
Antipyrine was analyzed at the College of Pharmacy, University of Kentucky, Lexington, by use of an established HPLC assay (4, 23) . A stock solution of phenacetin (0.5 ,ug/ml) was prepared in 100% HPLC-grade methanol to be used as the internal standard. One hundred microliters of the internal standard was pipetted into a glass test tube and dried under nitrogen gas. One hundred microliters of sample plasma was added to the test tube, and then 100 ,ul of 5 N NaOH and 1.0 ml of methylene chloride were added. After being vortexed for approximately 10 s, the tube was centrifuged (Beckman TJ6R) at 4,000 rpm for 5 min. The top (aqueous) plasma layer was vacuumed off. The bottom (methylene chloride) layer was poured into a clean glass test tube and dried under nitrogen gas. The samples were reconstituted with 100 ,ul of the mobile phase (see below), and 30 ,ul was injected into the HPLC. The HPLC system consisted of the following components: Shimadzu SPD-6AV UV-VIS spectrometric detector; Shimadzu LC-6A pump (flow rate, 1.0 ml/min); Shimadzu SCL-6B system controller; Shimadzu CF601 Chromatopac recorder/integrator; and Beckman Altex-Ultrasphere ODS column (C-18) (5-,um particle size; 4.6 mm by 25 Statistical analysis. Demographic data and baseline characteristics were analyzed by a one-way analysis of variance. A two-way analysis of variance with repeated measures for random study design (Statistical Analysis System) was used to determine the statistical significance of pharmacokinetic parameter differences between and within groups (i.e., healthy subjects versus subjects with cirrhosis and no ascites and versus subjects with cirrhosis and ascites) and treatments (i.e., oral versus i.v. administration). A P value of <0.05 was considered statistically significant (2) . Geometric regression was used to correlate the CLF of the metabolites with antipyrine clearances from the same subjects (17). 
RESULTS
All of the 24 enrolled subjects completed the study. One subject in cirrhotic group B received only 320 mg of the fleroxacin infusion owing to displacement of the venous catheter. Six of the 12 cirrhotic subjects (three each in groups A and B) suffered from alcohol-related liver cirrhosis, and 10 were taking concomitant medications, the most common being diuretics, laxatives, and vitamins. None of the subjects was actively drinking during the study. Three of the cirrhotic subjects had a diagnosis of liver cirrhosis confirmed by biopsy. In the other subjects, diagnosis was made on the basis of medical history, physical examination, and laboratory evaluation. Table 2 summarizes the demographic data and baseline characteristics of the subjects. Subjects were well matched for age, height, and weight (P > 0.05). The subjects in cirrhotic group A (ascites absent) had baseline characteristics similar to those of the subjects in the healthy volunteer group, except for a statistically significant increase in the prothrombin time (P < 0.05). The subjects in cirrhotic group B (ascites present) had baseline characteristics similar to those of the subjects in the healthy volunteer group, except for a statistically significant increase in the prothrombin time (P < 0.05). The subjects in cirrhotic group B (ascites present) had significantly lower antipyrine clearance (P < 0.01), creatinine clearance (P < 0.05), and serum albumin (P < 0.001) and significantly higher serum bilirubin (P < 0.05), serum glutamic oxalacetic transaminase (SGOT) (P < 0.0001), and prothrombin time (P < 0.01) than did the subjects in the healthy volunteer group and in the subjects in cirrhotic group A, respectively.
One subject from each study group group and cirrhotic group A (P > 0.05). The tl2 was significantly longer in cirrhotic group B than in healthy subjects (P < 0.001) and cirrhotic group A (P < 0.001). The CLs was only moderately lower in cirrhotic group A than in healthy volunteers (P > 0.05). However, the CLs was significantly lower in cirrhotic group B than in healthy volunteers (P < 0.001) and cirrhotic group A (P < 0.01). The average percentage of unchanged fleroxacin excreted in the urine ranged from 32.1 to 41.2% in all three groups (P > 0.05). The CLR was lower in all liver cirrhosis patients; however, only in the presence of ascites was this reduction significant (P < 0.001).
(ii) N-Demethyl fleroxacin. The tl2 of N-demethyl fieroxacin was significantly longer in cirrhotic group B than in healthy controls and cirrhotic group A (P < 0.001). The average percentage of N-demethyl fleroxacin excreted in the urine ranged from 4.0 to 5.9% in all three groups (P > 0.05). The CLR of this metabolite was significantly lower in cirrhotic group B than in healthy subjects (P < 0.01) and cirrhotic group A (P < 0.05). Also, the CLF was significantly lower in cirrhotic group B than in healthy volunteers and cirrhotic group A (P < 0.01). Figure 1 shows that the CLF of N-demethyl fleroxacin correlated well with the antipyrine clearance from the same subjects (r = 0.718; P < 0.001).
(iii) Fleroxacin N-oxide. The t112 of fleroxacin N-oxide in cirrhotic group B was significantly longer than those in healthy volunteers (P < 0.001) and cirrhotic group A (P < 0.01). The average percentage of fleroxacin N-oxide excreted in the urine ranged from 3.1 to 4.3% in all three groups (P > 0.05). The CLR of this metabolite was lower in cirrhotic group B than in healthy subjects (P < 0.05) and cirrhotic group A (P > 0.05). The CLF was significantly lower in 0.S. with an impairment of oxidative pathways. A 30 to 50% ANTPYRINE CLEARANCE (UA) decrease in cytochrome P-450 levels is seen in active liver 2. Correlation between the CLF of fleroxacin N-oxide and cirrhosis (9) . Consequently, the t112 values of both metaboipyrine clearance of the same subjects (r = 0.295;P > 0.05).
lites were two times longer in cirrhotic group B than in healthy controls. This change in the t112 values of the metabolites occurred in parallel with the change in the t12 of tic group B than in healthy controls (P < 0.01). The fleroxacin. Therefore, the elimination of the two main )f fleroxacin N-oxide did not correlate well with the metabolites appeared to be formation rate limited in all three rine clearance from the same subjects (r = 0.295; P > study groups (Fig. 3A to C). It has been hypothesized that two different enzyme systems are involved in the metabolism of fleroxacin (21) . DISCUSSION Demethylation is predominantly caused by cytochrome P-450, whereas N oxidation of xenobiotics containing nustudy was undertaken to examine the pharmacokicleophilic nitrogen atoms, as found in fleroxacin, is depen--hanges of fleroxacin, a fluoroquinolone characterized dent on flavoproteins. It is possible that flavoprotein activity zng t1,2 and a high bioavailability, in cirrhotic patients is influenced to a lesser degree by liver cirrhosis than is the nd without ascites.
P-450 mixed-function oxidase system of the liver (9, 13). Our ,hown previously (24) , the route of administration (i.v. study reflected the involvement of two different mechanisms oral) did not significantly influence fleroxacin dispoof metabolism of fleroxacin, as shown by the presence and in any of the three study groups. The pharmacokinetic absence of a relationship between metabolite CLF and eters determined in this study for healthy controls antipyrine clearance from the same subjects ( Fig. 1 and 2 ). in good agreement with previously published data (7, The CLF of N-demethyl fleroxacin correlated significantly 26) . The percentage of unchanged fleroxacin excreted with the antipyrine clearance (r = 0.718; P < 0.001), urine in this study appeared to be consistently lower suggesting the involvement of the cytochrome P-450 enzyme .hat reported by Weidekamm et al. (24, 25) . Other system. However, there was no relationship between the igators have reported lower or higher values for the CLF of fleroxacin N-oxide and the antipyrine clearance (r = itage of unchanged fleroxacin excreted (7, 11, 22) . The 0.295; P > 0.05), implying that N-oxide formation may not urinary recovery of fleroxacin in our investigation is be due to P-450 metabolism. When patients with ascites were ilained at this point. However, the CLR determined in considered alone in the regression analysis, they showed a udy was consistent with previously published results better relationship between the antipyrine clearance and the CLF of fleroxacin N-oxide. All patients with ascites had an rall, cirrhotics without ascites (cirrhotic group A) had antipyrine clearance of less than 2 liters/h and were comprone characteristics and pharmacokinetic parameters mised in their ability to form the N-oxide metabolite as well r to those of healthy controls. Group A cirrhotics had as the N-demethyl metabolite. Therefore, our results prosignificantly higher prothrombin time. However, we pose that the metabolic pathway of the N-oxide metabolite expect a reduced production of proteins, including may be affected by severe liver disease.
Ll clotting factors, in liver disease.
In all three study groups, CLR accounted for approxihotics with ascites (cirrhotic group B) showed signs of mately 40% and CLF accounted for 7 to 10% of the CLs of advanced liver disease with less hepatic reserve, fleroxacin, leaving approximately 50% of fleroxacin clearated by significantly less hepatic microsomal enzyme ance being unaccounted for. This observation is consistent ty (i.e., significantly lower antipyrine clearance), sig-with those of other studies (7, 22, 24, 26 pharmacokinetic parameters of fleroxacin occurred in cirrhotics without ascites. The CLs of fleroxacin was significantly lower in cirrhotics with ascites than in healthy controls and cirrhotics without ascites, partly because of significantly lower CLR and CLF in this patient population.
Our study results indicate that no dosage changes are necessary in cirrhotics without ascites. In cirrhotics with ascites, the loading dose does not require adjustment; however, a reduced daily maintenance dose, i.e., 200 mg once daily instead of 400 mg once daily, is recommended. 
